Critical Magnesium and HbA1c Cut-off Values for the Development of Polyneuropathy in Type 2 Diabetes Patients in Ankara City Hospital Between 2021-2023

Ayse Pinar Titiz^1,

¹Ankara City Hospital, Department of Neurology, Bilkent St. No: 1 Çankaya, Ankara 06800, Turkey

Cite this paper:
Ayse Pinar Titiz. Critical Magnesium and HbA1c Cut-off Values for the Development of Polyneuropathy in Type 2 Diabetes Patients in Ankara City Hospital Between 2021-2023. Journal of Food and Nutrition Research. 2024; 12(1):62-67. doi: 10.12691/jfnr-12-1-8

Abstract

Background and aim: Our aim was to evaluate the relationship between magnesium and HbA1c levels and the development of polyneuropathy (PNP) in patients with type 2 diabetes and to determine the cut-off values of magnesium (Mg) and HbA1c that may cause PNP. Methods: For all 270 patients with type 2 diabetes mellitus were performed electroneurographical examinations according to the polyneuropathy protocol, serum magnesium and HbA1c levels were measured and recorded. Results: The mean age was higher in the group with PNP. The distribution of sex ratios among the PNP groups was statistically different, with more males in the PNP group (P=0.016). Mg values were statistically lower in patients with PNP (P<0.001). HbA1c values were statistically higher in patients with PNP (P=0.013). Patients with Mg values less than or equal to 1.95mg/dl were 11.3 times and patients with HbA1c values greater than or equal to 8.95mmol/mol were 3.9 times more likely to develop PNP. Conclusions: Although the lower normal limit for Magnesium was 1.6mg/dl and the upper limit for HbA1c was 6.3mmol/mol according to our laboratory standards, we found a more real cut-off value in terms of predisposing to the development of polyneuropathy in our patients.

Keywords:
hypomagnesemia HbA1c type 2 diabetes mellitus cut-off polyneuropathy

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Pop-Busui, R., Boulton, A.J., Feldman, E.L., et al. Diabetic neuropathy: a position statement by the American diabetes association. Diabetes Care 2017; 40(1): 136e154.
[2]	Ziegler, D., Papanas, N., Schnell, O., et al. Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig 2021; 12: 464–475.
[3]	Han, J.W., Sin, M.Y., Yoon, Y.S. Cell therapy for diabetic neuropathy using adult stem or progenitor cells. Diabetes Metab J 2013; 37(2): 91-105.
[4]	Kundu, D., Osta, M., Mandal, T., Bandyopadhyay, U., Ray, D., Gautam, D. Serum magnesium levels in patients with diabetic retinopathy. J Nat Sci Biol Med 2013; 4(1): 113-6.
[5]	Glasdam, S.M., Glasdam, S., Peters, G.H. The Importance of Magnesium in the Human Body: A Systematic Literature Review. Advances in Clinical Chemistry 2016; 73: 169-193.
[6]	Baig, M.S.A., Shamshuddin, M., Mahadevappa, K.L., Attar, A.H., Shaikh, A.K. Serum Magnesium as a Marker of Diabetic Complication. Journal of Evolution of Medical & Dental Sciences 2012; 1: 119-123.
[7]	Mishra, S., Padmanaban, P., Deepti, G.N., Sarkar, G., Sumathi, S. and Toora, B.D. Serum Magnesium and Dyslipidemia in Type-2 Diabetes Mellitus. Biomedical Research 2012; 23: 295-300.
[8]	Feng, J., Wang, H., Jing, Z., et al. Relationships of the Trace Elements Zinc and Magnesium With Diabetic Nephropathy-Associated Renal Functional Damage in Patients With Type 2 Diabetes Mellitus. Frontiers in Medicine 2021 Mar 30; 8: 626909.
[9]	Pham, P.C., Pham, P.M., Pham, S.V., Miller, J.M., Pham, P.T. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2(2): 366-73.
[10]	De Leeuw, I., Engelen, W., De Block, C., Van Gaal, L. Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). Magnes Res 2004; 17(2): 109-14.
[11]	Kurstjens, S., Baaij, J.H.F., Bouras, H., Bindels, R.J.M., Tack, C.J.J., Hoenderop, J.G.J. Determinants of hypomagnesemia in patients with type 2 diabetes mellitus. European Journal of Endocrinology 2017; 176, 11–19.
[12]	Chu, C., Zhao, W., Zhang, Y., et al. Low serum magnesium levels are associated with impaired peripheral nerve function in type 2 diabetic patients. Scientific Reports 2016; 6:32623.
[13]	Jamali, A.A., Jamali, G.M., Tanwani, B.J., Jamali, A.A., Tanwani, J., Jamali, N.M. Association of Hypomagnesemia in Type 2 Diabetic Patients with and without Peripheral Neuropathy. Journal of Diabetes Mellitus 2018, 8, 27-42.
[14]	Mete, T., Aydin, Y., Saka, M., et al. Comparison of Efficiencies of Michigan Neuropathy Screening Instrument, Neurothesiometer, and Electromyography for Diagnosis of Diabetic Neuropathy. Int J Endocrinol 2013; 2013: 821745.
[15]	Watson, J.C. and Dyck, P.J. Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management. Mayo Clinic Proceedings 2015; 90: 940-951.
[16]	Arpaci, D., Tocoglu, A.G., Ergenc, H., Korkmaz, S., Ucar, A. and Tamer, A. Associations of Serum Magnesium Levels with Diabetes Mellitus and Diabetic Complications. Hippokratia 2015; 19: 153-157.
[17]	Martyn, C.N. and Hughes, R.A. Epidemiology of Peripheral Neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 1997; 62: 310-318.
[18]	Abosrea, M.A., Elmasry, H.A., Oraby, M.I. Gender differences in Diabetic Peripheral Neuropathy. Egyptian Journal of Medical Research 2020; 1(1): 1-10.
[19]	Kaplan, Y., Kurt, S., Ünaldı, H.K., Erkorkmaz, Ü. Risk factors for diabetic polyneuropathy. Archives of Neuropsychiatry 2014; 51: 11-14.
[20]	Barbosa, A.P., Medina, J.L., Ramos, E.P., Barros, H.P. The DPN in Porto Study Group. Prevalence and risk factors of clinical diabetic polyneuropathy in a Portuguese primary health care population. Diabetes Metab. 2001; 27: 496–502.
[21]	Booya, F., Bandarian, F., Larijani, B., Pajouhi, M., Nooraei, M. and Lotfi, J. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurology 2005; 5, 24.
[22]	Aaberg, M., Burch, D., Hud, Z. and Zacharias, M. Gender differences in the onset of diabetic neuropathy. Journal of Diabetes and Its Complications 2008; 22(2): 83-87.
[23]	Tamer, A., Yıldız, S., Yıldız, N., et al. The prevalence of neuropathy and relationship with risk factors in diabetic patients: a single-center experience. Med Princ Pract. 2006; 15: 190–194.
[24]	Strom, A., Strassburger, K., Schmuck, M., et al. Molecular Metabolism 2020; 43(1): 1011142020.
[25]	Mooren, F.C. Magnesium and disturbances in carbohydrate metabolism. Diabetes, Obesity and Metabolism 2015; 17(9): 813-823.
[26]	Gommers, L.M., Hoenderop, J.G., Bindels, R.J., de Baaij, J.H. Hypo-magnesemia in type 2 diabetes: a vicious circle? Diabetes 2016; 65(1): 3-13.